Article in Cancer research communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
31 authors.
Roni HaasDepartment of Human Genetics, University of California, Los Angeles, Los Angeles, California.ORCID 0000-0003-1505-2965
Gavin FrameDepartment of Medical Biophysics, University of Toronto, Toronto, Canada.ORCID 0009-0004-2924-134X
Shahbaz KhanPrincess Margaret Cancer Centre, University Health Network, Toronto, Canada.ORCID 0009-0003-8690-3090
Beth K NeilsenDepartment of Human Genetics, University of California, Los Angeles, Los Angeles, California.ORCID 0000-0002-4859-6486
Boon Hao HongDivision of Medical Sciences, National Cancer Centre Singapore, Singapore, Singapore.ORCID 0000-0002-2822-7480
Celestia P X YeoDivision of Medical Sciences, National Cancer Centre Singapore, Singapore, Singapore.ORCID 0009-0000-7950-2254
Takafumi N YamaguchiDepartment of Human Genetics, University of California, Los Angeles, Los Angeles, California.ORCID 0000-0003-1082-3871
Enya H W OngDivision of Medical Sciences, National Cancer Centre Singapore, Singapore, Singapore.ORCID 0000-0002-2591-7910
Wenyan ZhaoDepartment of Human Genetics, University of California, Los Angeles, Los Angeles, California.ORCID 0000-0001-9647-8006
Benjamin CarlinDepartment of Human Genetics, University of California, Los Angeles, Los Angeles, California.ORCID 0000-0002-9360-9143
Eugenia L L YeoDivision of Medical Sciences, National Cancer Centre Singapore, Singapore, Singapore.ORCID 0000-0002-3639-7404
Kah Min TanDivision of Medical Sciences, National Cancer Centre Singapore, Singapore, Singapore.ORCID 0009-0000-7535-8734
Yuan Zhe BughDepartment of Human Genetics, University of California, Los Angeles, Los Angeles, California.ORCID 0000-0002-3662-3475
Chenghao ZhuDepartment of Human Genetics, University of California, Los Angeles, Los Angeles, California.ORCID 0000-0003-1674-4533
Rupert Hugh-WhiteDepartment of Human Genetics, University of California, Los Angeles, Los Angeles, California.ORCID 0000-0003-3351-8925
Julie LivingstoneDepartment of Human Genetics, University of California, Los Angeles, Los Angeles, California.ORCID 0000-0002-8424-3768
Dennis J J PoonDivision of Medical Sciences, National Cancer Centre Singapore, Singapore, Singapore.ORCID 0009-0000-5822-6617
Pek Lim ChuDivision of Medical Sciences, National Cancer Centre Singapore, Singapore, Singapore.ORCID 0009-0009-3840-4792
Yash PatelDepartment of Human Genetics, University of California, Los Angeles, Los Angeles, California.ORCID 0000-0003-3113-7010
Shu TaoDepartment of Human Genetics, University of California, Los Angeles, Los Angeles, California.ORCID 0000-0001-5177-6771
Vladimir IgnatchenkoPrincess Margaret Cancer Centre, University Health Network, Toronto, Canada.ORCID 0009-0007-7457-7274
Natalie J KurganovsPrincess Margaret Cancer Centre, University Health Network, Toronto, Canada.ORCID 0000-0002-8555-5528
Geoff S HigginsDepartment of Oncology, University of Oxford, Oxford, United Kingdom.ORCID 0000-0003-3072-909X
Michelle R DownesDivision of Anatomic Pathology, Laboratory Medicine and Molecular Diagnostics, Sunnybrook Health Sciences Centre, Toronto, Canada.ORCID 0000-0002-4528-3724
Andrew LoblawSunnybrook Research Institute, Sunnybrook Health Sciences Centre, Toronto, Canada.ORCID 0000-0002-4883-1781
Danny VespriniSunnybrook Research Institute, Sunnybrook Health Sciences Centre, Toronto, Canada.ORCID 0000-0001-9714-2782
Amar U KishanDepartment of Radiation Oncology, University of California, Los Angeles, Los Angeles, California.ORCID 0000-0002-4836-8483
Melvin L K ChuaDivision of Medical Sciences, National Cancer Centre Singapore, Singapore, Singapore.ORCID 0000-0002-1648-1473
Thomas KislingerDepartment of Medical Biophysics, University of Toronto, Toronto, Canada.ORCID 0000-0003-3525-5540
Paul C BoutrosDepartment of Human Genetics, University of California, Los Angeles, Los Angeles, California.ORCID 0000-0003-0553-7520
Stanley K LiuDepartment of Medical Biophysics, University of Toronto, Toronto, Canada.ORCID 0000-0001-6851-0857
Funding
Integrative Cancer Scholars Training GrantT32CA009213 · NCI · UNIVERSITY OF ARIZONA · PI CAREW, JENNIFER S, CURIEL-LEWANDROWSKI, CLARA · 1985 to 2024
$8.6M
Advancing method benchmarking and data sharing through crowd-sourced competitions in cancer researchU24CA248265 · NCI · SAGE BIONETWORKS · PI BOUTROS, PAUL CHRISTOPHER, VARMA, SUSHEEL · 2020 to 2024
$4.1M
Virginia-UCLA-Toronto Biomarker Characterization CenterU2CCA271894 · NCI · OLD DOMINION UNIVERSITY · PI OLIVER John SEMMES · 2022 to 2026
$3.2M
Biomedical Data Science Training Program for Precision Health EquityT15LM013976 · NLM · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ALEX BUI · 2022 to 2026
$1.9M
Cancer Research UK 28736NCI NIH HHS T32 CA009213NCI NIH HHS U24 CA248265NCI NIH HHS U2C CA271894NLM NIH HHS T15 LM013976
6 · The paper itself
Abstract
Prostate cancer is frequently treated with radiotherapy. Unfortunately, aggressive radioresistant relapses can arise, and the molecular underpinnings of radioresistance are unknown. Modern clinical radiotherapy is evolving to deliver higher doses of radiation in fewer fractions (hypofractionation). We therefore analyzed genomic, transcriptomic, and proteomic data to characterize prostate cancer radioresistance in cells treated with both conventionally fractionated and hypofractionated radiotherapy. Independent of fractionation schedule, resistance to radiotherapy involved massive genomic instability and abrogation of DNA mismatch repair. Specific prostate cancer driver genes were modulated at the RNA and protein levels, with distinct protein subcellular responses to radiotherapy. Conventional fractionation led to a far more aggressive biomolecular response than hypofractionation. Testing preclinical candidates identified in cell lines, we revealed POLQ (DNA Polymerase Theta) as a radiosensitizer. POLQ-modulated radioresistance in model systems and was predictive of it in large patient cohorts. The molecular response to radiation is highly multimodal and sheds light on prostate cancer lethality. SIGNIFICANCE: Radiation is standard of care in prostate cancer. Yet, we have little understanding of its failure. We demonstrate a new paradigm that radioresistance is fractionation specific and identified POLQ as a radioresistance modulator.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
The Proteogenomics of Prostate Cancer Radioresistance. · full record | OpenQuestion